Rigel Pharmaceuticals' R289 Shows Promise in Treating Lower-Risk Myelodysplastic Syndrome

Rigel Pharmaceuticals Advances in MDS Treatment with R289 Data

Rigel Pharmaceuticals, Inc. reports encouraging preliminary efficacy results from its Phase 1b study of R289, an oral prodrug of R835, aimed at treating patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS). During the 67th American Society of Hematology Annual Meeting, Dr. Guillermo Garcia-Manero presented the findings, highlighting a transfusion independence rate of 33% among transfusion-dependent patients taking doses of 500 mg once daily or higher. Notably, this rate improves to 40% for those receiving 500 mg twice daily. These results offer hope for a patient population that often faces limited treatment options due to the complex nature of their condition.

The study included 33 participants, predominantly elderly with a median age of 75, many of whom have undergone extensive prior therapies, averaging three. A significant 76% of these patients had previously received luspatercept, a treatment that underscores the challenging nature of their medical history. Furthermore, 61% of the enrolled patients were identified as having a high transfusion burden, indicating a severe need for effective therapies. Rigel’s Chief Medical Officer, Dr. Lisa Rojkjaer, emphasizes the critical demand for new treatment avenues in this area, expressing optimism about R289's potential to become a viable option for those afflicted with lower-risk MDS.

R289 shows a favorable safety profile, with treatment-emergent adverse events primarily consisting of diarrhea (30%) and fatigue (27%), suggesting that the drug is generally well tolerated within the studied population. The median duration of treatment among participants is 5.5 months, reflecting sustained engagement with the therapy in this heavily pre-treated cohort. The study aims to complete its dose expansion phase by the second half of 2026, planning to randomize up to 40 patients to identify the recommended Phase 2 dose. This development signals a significant step forward for Rigel Pharmaceuticals in addressing the needs of patients suffering from MDS.

In a broader context, the advancements in MDS treatment reflect the ongoing challenges faced by biotechnology companies like Rigel Pharmaceuticals. The need for innovative therapies is compelling as patient demographics become increasingly complex. The positive data from the R289 study not only reinforces Rigel's commitment to addressing hematologic disorders but also underscores the potential for significant improvements in patient outcomes with new therapeutic approaches. The anticipated conclusions from the ongoing study hold promise for future clinical applications and underscore the importance of continued research in this vital area of medicine.